| Document |
Document Title |
|
WO1997035591B1 |
A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as u...
|
|
WO/2001/029055A2 |
The invention concerns oligosaccharides of formula (I), their mixtures, their diastereomers, methods for preparing them and pharmaceutical compositions containing them.
|
|
WO/2001/029045A1 |
The compounds of formula (I) and (II) including pharmaceutically acceptable salts, stereoisomers or esters thereof are disclosed.
|
|
WO/2001/027131A1 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compoun...
|
|
WO/2001/027114A1 |
Compositions and methods for pyrrolo[2,3-d]pyrimidine nucleoside analogs having substituents at the C4' and C5' positions of the ribofuranose moiety are presented. Contemplated compositions exhibit, among other things, anti-cancer and im...
|
|
WO/2001/027130A1 |
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such com...
|
|
WO/2001/026482A1 |
A composition, preferably used to reduce methane formation in a ruminant, wherein the composition is a combination of a polycyclic quinone compound and an ionophore compound.
|
|
WO1999063939A9 |
Disclosed are multibinding compounds which inhibit cyclooxygenase-2 (COX-2), an enzyme which catalyzes the first committed step in the biosynthesis of prostaglandins. The multibinding compounds of this invention containing from 2 to 10 l...
|
|
WO/2001/025247A1 |
A hydrocarbyldithiomethyl-modified compound of the Formula (1): R?1¿-O--CH¿2?-S-S-R?2¿, or a salt thereof wherein R?1¿ is an organic molecule and R?2¿ is a hydrocarbyl, is useful for protecting and/or blocking hydroxyl groups in org...
|
|
WO/2001/025248A2 |
The present invention relates to the field of bicyclic DNA analogues, e.g. LNA and LNA modifications, which are useful for designing oligomers that form high affinity duplexes with complementary RNA wherein said duplexes are substrates f...
|
|
WO/2001/023399A1 |
A¿3? agonists, methods of using such A¿3? agonists and pharmaceutical compositions containing such A¿3? agonists. The A¿3? agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.
|
|
WO/2001/023400A1 |
Highly pure guanosine 5'-diphosphate fucose (GDP-Fuc) having such a purity as specified below. (1) Guanosine 5'-diphosphate fucose (GDP-Fuc): 95% or more. (2) Guanosine 5'-diphosphate (GDP): 3% or less. A process for producing highly pur...
|
|
WO2000032823A9 |
The invention provides methods for covalently tagging proteins with their encoding DNA sequences as shown in the Figure. These DNA-protein fusions may be used in molecular evolution and recognition techniques.
|
|
WO/2001/020040A2 |
A method for estimating the location of the crossover point of a polymer separation system, the method comprising: (a) electrophoresing a plurality of polynucleotide pairs through a polymer separation system, wherein each polynucleotide ...
|
|
WO/2001/018015A1 |
Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3'-NHP(O)(S?-¿)O-5' linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphorami...
|
|
WO/2001/016150A2 |
Compounds having structure (I) where X is CH or N, Y is -CO-, -CONW-, -O-, -S-, -SO-, -SO¿2?-, -NWCO-, -NW-, or -OCO-, W is the same or different at different places in the molecule and each is H or alkyl or aryl or Rp or -Ln-Rp, Ln is ...
|
|
WO/2001/016365A1 |
A compound comprising a poly(ether-thioether), poly(ether-sulfoxide) or poly(ether-sulfone) backbone bearing a plurality of ligands that are individually bound to chiral carbon atoms located within the backbone, at least one of the ligan...
|
|
WO/2001/016151A1 |
A novel technical means of achieving a highly selective coupling yield, enabling coupling site-specific photocleavage and freely and reversibly controlling photocoupling and photocleavage. A reversible photocoupling nucleic acid represen...
|
|
WO/2001/016369A2 |
Novel energy transfer dyes which can be used with shorter wavelength light sources are provided. These dyes include a donor dye with an absorption maxima at a wavelength between about 250 to 450 nm and an acceptor dye which is capable of...
|
|
WO/2001/016149A2 |
Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore,...
|
|
WO/2001/016312A2 |
Nucleic acid molecules (antisenses or ribozymes) useful as inhibitors of gene expression, especially of HER2, BACE, TERT, PTP-1B, MetAP-2, HBV, phospholamban, presenilin-2 and PKC-alpha. The nucleic acid molecules can be modified in vari...
|
|
WO/2001/014399A1 |
Compounds of general formula (I) or pharmacologically acceptable derivatives or salts thereof; compositions for the prevention or treatment of bacterial infections, containing the compounds, the derivatives or the salts as the active ing...
|
|
WO/2001/014401A1 |
Novel compounds are provided in the form of nucleoside pyrophosphate and triphosphate analogs. In these analogs, the pyrophosphate or triphosphate group is replaced with a moiety that is isosterically and electronically identical thereto...
|
|
WO/2001/014345A1 |
Disclosed are 5-propynylpyrimidine derivatives of formula (I) wherein X is a leaving group, R¿1? is selected from the group consisting of -OH,-NH¿2?, and -SH; R¿2? is selected from the group consisting of -H, 2-deoxyribose and ester d...
|
|
WO/2001/014400A1 |
Nucleosidic monomers and oligomeric compounds prepared therefrom are provided. Also provided is a novel method of deprotection of oligomeric compounds. Oligomeric compounds having at least one 2'-O-acetamido modified nucleosidic monomer ...
|
|
WO/2001/012644A1 |
The present invention relates to the art of molecular biology and, more specifically, to novel dinucleoside 5',5'-tetraphosphate derivatives which are selective inhibitors of the reproduction of the human immunodeficiency virus (HIV) and...
|
|
WO/2001/012642A2 |
Disclosed are novel nucleoside derivatives of general formula (I), wherein R¿1? represents a nucleobase or a nucleobase that is provided with at least one protective group, R¿2? means an H atom or a diisopropylamino-(2-cyanoethoxy)-pho...
|
|
WO/2001/012643A1 |
Caprazamycins A to F, which are antibiotics represented by general formula (I), are obtained by culturing Streptomyces sp. MK730-62F2 (FERM BP-7218). These caprazamycins have excellent antibacterial activities on various mycobacteria, ba...
|
|
WO/2001/009390A1 |
Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are me...
|
|
WO/2001/009156A1 |
Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF$g(b)2. Included in the invention are specific RNA ligands to TGF$g(b)2 identified by the SELEX method. Also included are RNA ligand...
|
|
WO/2001/007088A2 |
This invention provides a method for selectively inhibiting a pathological cell, wherein the cell is characterized by expression of an endogenous, intracellular activating enzyme and wherein the enzyme is not inactivated by a substrate p...
|
|
WO/2001/007454A1 |
This invention provides novel substrate compounds that selectively inhibit the proliferation of pathological cells, for example, pathological cells that endogenously overexpress a target enzyme that confers resistance to biologic and che...
|
|
WO/2001/007455A1 |
Novel bicyclonucleoside analogues having an anti-AIDS activity; and intermediates for the preparation of oligonucleotide analogues having an excellent antisense or antigene activity and being stable in vivo. Specifically, compounds repre...
|
|
WO2000008041A9 |
A compound of a general structure: D-B-M , wherein B is selected from the group consisting of derivatives of naturally occurring nitrogenous bases having a C-H group of positions 5 or 8, and derivatives of nitrogenous base-analogs having...
|
|
WO/2001/006986A2 |
The present invention relates to pyrimidine nucleoside compounds and their use to treat viral infections of Varicella Zoster Virus, Epstein Barr Virus and Kaposi's Sarcoma virus, also known as HV-8 and related complications of these vira...
|
|
WO/2001/007087A2 |
This invention provides a method for selectively inhibiting an infectious agent or a cell infected by an infectious agent by contacting the infectious agent or the cell infected with the agent with a prodrug that is selectively converted...
|
|
WO/2001/005801A1 |
A novel artificial nucleic acid base pair which is obtained by forming a selective base pair by introducing a group having steric hindrance (preferably a group having steric hindrance and static repulsion and a stacking effect) and can b...
|
|
WO/2001/005773A1 |
Compounds of the general formula P¿1?-L-P¿2?; wherein 'P¿1?' is a pyrazinoylguanidine sodium channel blocker, 'L' is a linking group, and 'P¿2?' is either (i) a pyrazinoylguanidine sodium channel blocker or (ii) a P2Y¿2? receptor ag...
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
WO/2001/004134A2 |
The invention concerns the field of organic chemistry, and more precisely, that of therapeutic chemistry. More particularly, the invention concerns novel esters derived from nucleosides of general formula (I) wherein: A represents a diva...
|
|
WO/2001/002419A1 |
The present invention is directed to nucleotide monomers wherein the 3'-O atom is replaced with a methylene group. The present invention also provides oligomers comprising a plurality of such monomers which are linked by methylene phosph...
|
|
WO/2001/002417A1 |
The present invention relates to antisense monomers and oligomers which can inhibit transcription for the production of disease-inducing proteins. The antisense monomers and oligomers of the present invention have greater binding affinit...
|
|
WO/2001/002415A1 |
The present invention is directed to nucleoside monomers wherein the 3'-O atom is replaced with a methylene group. The present invention also provides oligomers comprising a plurality of such monomers which are linked by methylenephospho...
|
|
WO/2001/002020A2 |
Novel pro-drugs and methods for their use to alter the growth and biological characteristics of living cells, tissues, or whole organisms are described. The methods allow for selective activation of the pro-drugs at or near transformant ...
|
|
WO/2001/000627A1 |
The invention provides compounds of formula (1) wherein R?1¿ is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms; and R?2¿ is a hydrogen atom, an alkyl group having 1 to 6 carbon ...
|
|
WO2000029420A9 |
The invention is directed to novel methods of making nucleosides modified with signalling moieties and polydentate ligands, particularly for use in chelating transition metal complexes to form signalling moieties such as electron transfe...
|
|
WO/2001/000641A1 |
Compounds of the structural formula (1) or pharmacologically acceptable salts thereof, useful as intermediates for the preparation of nonnatural oligonucleotide analogues or 2-5A analogues which exhibit an excellent antisense or antigene...
|
|
WO/2000/078775A1 |
Compounds represented by general formula (1) and salts thereof: wherein R?1¿ and R?2¿ are each independently hydrogen, a hydroxyl-protecting group, a phosphate group or -P(R?3¿)R?4¿ [wherein R?3¿ and R?4¿ are each independently hyd...
|
|
WO/2000/078777A1 |
2-adenosine propargyl phenyl ether compounds having formula (A) and methods for using the compounds as A¿2A? receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
|
|
WO/2000/078779A2 |
2-Adenosine N-pyrazole compounds having formula (1) and methods for using compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
|
